PERSPECTA

News from every angle

← Back to headlines

Merck's Cholesterol Drug Meets Main Goal in Head-to-Head Trial

A late-stage trial of a new Merck drug demonstrated a reduction in bad cholesterol by up to 64.6%, meeting its main goal in a head-to-head trial.

30 Mar, 16:09 — 30 Mar, 16:09
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual31d ago

Merck's drug reduced bad cholesterol by up to 64.6% in late-stage trial

Read full article →

Coverage Timeline

First report: Yahoo · 30 Mar, 16:09Full coverage: 2 · 4hWindow: 4h
Left-leaningCenterRight-leaning
Yahoo30 Mar, 16:09First to report

Merck's drug reduced bad cholesterol by up to 64.6% in late-stage trial

4h later
Reuters30 Mar, 19:42Latest update

Merck's cholesterol drug meets main goal in head-to-head trial - Reuters

Related Stories

Philippine Charity Sweepstakes Office Provides ₱18.2M Aid to Mindoro Healthcare

just now

NGO Provides Health Insurance for Pregnant Women in Enugu

just now

Philippines clears irrigation canals in Bicol to mitigate El Niño impact

just now

Kwara State Government Pledges Improved Immunisation Efforts

just now